Semaglutide & Tirzepatide
Also known as: GLP-1 vs dual GIP/GLP-1 comparison entry
Semaglutide & Tirzepatide (also called GLP-1 vs dual GIP/GLP-1 comparison entry) is a research peptide in the GLP-1 Agonist class. This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- See individual products (~5–7 days)
- FDA status
- Approved
- Administration Route
- Subcutaneous
- Frequency
- 1× weekly
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- GLP-1 receptorGIP receptor (tirzepatide)
Research summary
Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Not a single combination drug.
Peptide Library's Semaglutide & Tirzepatide profile summarises 3 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Semaglutide: 0.25→2.4 mg weekly; Tirzepatide: 2.5→10–15 mg weekly (titrate)
- Frequency
- 1× weekly
- Cycle
- Long-term use for obesity/diabetes; reassess periodically
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThighUpper arm
- Timing Notes
- Same day each week; evening if nausea-prone When stacking different classes, space injections by 15–30 minutes; do not mix in the same syringe unless verified compatible.
- Expected Onset
- 1–4 weeks (appetite), 8–12+ weeks (weight)
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Semaglutide & Tirzepatide is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Half-life | See individual products (~5–7 days) |
|---|---|
| Appearance | Prefilled pen (Rx) or research vials (where applicable) |
| Formulation | Prefilled Pen |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction. Tirzepatide activates both the GIP and GLP-1 receptors from a single peptide, with agonism weighted toward GIPR and biased signalling at GLP-1R that limits receptor desensitisation. The added GIP activity is the pharmacological difference, and head-to-head trial data in obesity has shown greater mean weight reduction with tirzepatide. Both are prescription medicines with class-typical gastrointestinal effects.
Origin
Two separate approved peptide drugs.
Targets
Studies
- Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies
- Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes
- Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
Regulatory & research status
Semaglutide & Tirzepatide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Availability | Prescription-Only |
| WADA (sport) | Permitted |
| Library classification | FDA-Approved |
Benefits
Semaglutide & Tirzepatide side effects
Side Effects
- Shared GI class effects
Contraindications
- Titrate slowly to manage GI effects; follow Rx guidance
Stacking
Common stacking partners
Combinations that include Semaglutide & Tirzepatide, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Semaglutide & Tirzepatide: frequently asked questions
What is Semaglutide & Tirzepatide?
Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Not a single combination drug.
How does Semaglutide & Tirzepatide work?
This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction.
Is Semaglutide & Tirzepatide FDA approved?
Yes. Semaglutide & Tirzepatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What is the half-life of Semaglutide & Tirzepatide?
Reported half-life for Semaglutide & Tirzepatide is See individual products (~5–7 days). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Semaglutide & Tirzepatide banned in sport?
Semaglutide & Tirzepatide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Semaglutide & Tirzepatide?
Compounds most often compared with Semaglutide & Tirzepatide include Amycretin, CagriSema, Cotadutide and Dulaglutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Wegovy labelExternal reference
- Zepbound labelExternal reference
- Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies — Endocrinol Diabetes Metab, 2025External reference
- Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes — JAMA Netw Open, 2025External reference
- Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis — Front Pharmacol, 2025External reference
Related research, comparisons & guides
- Tirzepatide vs. Semaglutide: What the Head-to-Head Trial Actually Found
- Semaglutide Dosage Chart: The Escalation Steps and What They Are in Units
- Tirzepatide Dosage Chart: Milligrams, and What They Are in Syringe Units
- Peptide dosage chart: dose, route and frequencyCategory
- Peptide calculator with the Semaglutide & Tirzepatide preset
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Semaglutide & Tirzepatide profile is compiled from published literature (3 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Semaglutide & Tirzepatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →